Global Pandemic COVID-19 (2019-nCoV): Novel Deadliest Contagion

M. Patel
{"title":"Global Pandemic COVID-19 (2019-nCoV): Novel Deadliest Contagion","authors":"M. Patel","doi":"10.14293/s2199-1006.1.sor-.ppa8ctd.v1","DOIUrl":null,"url":null,"abstract":"Global pandemic cause by coronavirus has been reported in Wuhan, China; in late December 2019. Within time duration of few weeks, the newly identified virus designated as 2019-Novel Coronavirus (2019-nCoV) and it was declared by World Health Organization (WHO). At the time of late January 2020, WHO announced it as the international emergency outbreak because of the rapid spread and increases at the global level. There is no any preventive vaccine is present or any approved therapy/treatment for this viral emergency which is very infectious globally. Till the previous few decades, six strains of coronaviruses were found, but in Wuhan, China in December 2019, a totally new strain of coronavirus was spread across the city. Within few days, it was designated as the novel coronavirus abbreviated as 2019-nCoV by World Health Organization. The rate of virus progression is still not determined and that is why it is very difficult to find the patient zero which is very essential. Phylogenetic analysis of the virus specifies bat origin of 2019-nCoV, its transmission is airborne i.e. human to human, infected person can be identified having the primary symptoms which includes high fever, upper or lower respiratory tract infection. Its diagnosis at the molecular level includes Real-Time PCR for encoding genes for the internal transcribed RNA-dependent RNA polymerase and Spike protein receptor binding domain. It can be confirmed by the Sanger Sequencing including full genome analysis by Next Generation Sequencing, multiplex nucleic acid amplification and microarray based analysis. There are few mRNA vaccines which were developed by few Biotechnology companies, showing positive results against COVID-19 and it is there in 4th phase clinical trial which possibly be the first vaccine available in the market in between mid-2021.","PeriodicalId":21568,"journal":{"name":"ScienceOpen Posters","volume":"99 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ScienceOpen Posters","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14293/s2199-1006.1.sor-.ppa8ctd.v1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Global pandemic cause by coronavirus has been reported in Wuhan, China; in late December 2019. Within time duration of few weeks, the newly identified virus designated as 2019-Novel Coronavirus (2019-nCoV) and it was declared by World Health Organization (WHO). At the time of late January 2020, WHO announced it as the international emergency outbreak because of the rapid spread and increases at the global level. There is no any preventive vaccine is present or any approved therapy/treatment for this viral emergency which is very infectious globally. Till the previous few decades, six strains of coronaviruses were found, but in Wuhan, China in December 2019, a totally new strain of coronavirus was spread across the city. Within few days, it was designated as the novel coronavirus abbreviated as 2019-nCoV by World Health Organization. The rate of virus progression is still not determined and that is why it is very difficult to find the patient zero which is very essential. Phylogenetic analysis of the virus specifies bat origin of 2019-nCoV, its transmission is airborne i.e. human to human, infected person can be identified having the primary symptoms which includes high fever, upper or lower respiratory tract infection. Its diagnosis at the molecular level includes Real-Time PCR for encoding genes for the internal transcribed RNA-dependent RNA polymerase and Spike protein receptor binding domain. It can be confirmed by the Sanger Sequencing including full genome analysis by Next Generation Sequencing, multiplex nucleic acid amplification and microarray based analysis. There are few mRNA vaccines which were developed by few Biotechnology companies, showing positive results against COVID-19 and it is there in 4th phase clinical trial which possibly be the first vaccine available in the market in between mid-2021.
全球大流行COVID-19 (2019-nCoV):新型致命传染病
中国武汉报告了冠状病毒引起的全球大流行;2019年12月下旬。在几周的时间内,新发现的病毒被指定为2019-新型冠状病毒(2019-nCoV),并被世界卫生组织(世卫组织)宣布。2020年1月下旬,由于疫情在全球范围内迅速蔓延和增加,世卫组织宣布其为国际紧急疫情。对于这种全球传染性很强的病毒紧急情况,目前没有任何预防性疫苗或任何批准的治疗/治疗方法。在过去的几十年里,人们发现了六种冠状病毒,但2019年12月,在中国武汉,一种全新的冠状病毒在整个城市传播。几天后,它被世界卫生组织指定为新型冠状病毒(简称2019-nCoV)。病毒进展的速度仍然没有确定,这就是为什么很难找到零号病人的原因,这是非常重要的。该病毒的系统发育分析明确了2019-nCoV的蝙蝠来源,其传播方式是空气传播,即人与人之间的传播,可确定感染者具有主要症状,包括高烧、上呼吸道或下呼吸道感染。在分子水平上的诊断包括Real-Time PCR,用于编码内部转录RNA依赖性RNA聚合酶和Spike蛋白受体结合域的基因。通过Sanger测序,包括下一代测序的全基因组分析,多重核酸扩增和基于微阵列的分析,可以证实这一点。很少有生物技术公司开发的mRNA疫苗显示出对COVID-19的积极效果,并且正在进行第四阶段临床试验,可能在2021年中期之间成为市场上第一种疫苗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信